RYTHM Reports Q4 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy RYM?
Source: seekingalpha
- Financial Highlights: RYTHM reported a GAAP EPS of -$6.63 for Q4, indicating significant losses; however, revenue surged by 167.5% year-over-year to $10.7 million, showcasing strong momentum in revenue growth.
- Revenue Growth Analysis: The revenue increase was primarily driven by the launch of new products and rising market demand, which not only enhanced the company's market share but also laid the groundwork for future profitability.
- Market Reaction: Despite the substantial revenue growth, the negative EPS may pressure investor confidence, leading to stock price volatility and reflecting market concerns regarding the company's financial health.
- Future Outlook: RYTHM must implement effective measures in upcoming quarters to improve profitability in order to maintain competitiveness in a growing market, especially in light of potential investor skepticism.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYM
About RYM
RYTHM, Inc., formerly Agrify Corporation, is a provider of branded innovative solutions for the cannabis and hemp industries. The Company’s portfolio of brands includes RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, & Shine, Doctor Solomon’s and Good Green in thousands of physical locations and online channels. The Company’s portfolio of consumer-packaged goods brands includes Senorita brand which offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror well-known cocktails like a margarita in four flavors, including classic Lime JalapeNo Margarita, Mango Margarita, Paloma and Ranch Water. Senorita offers a low-sugar, low-calorie alternative to alcoholic beverages and is available at retailers, including Total Wine, ABC Fine Wine & Spirits, and Binny’s in 11 U.S. states and Canada. Its comprehensive extraction product line includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RYTHM Reports Q4 Financial Results
- Financial Highlights: RYTHM reported a GAAP EPS of -$6.63 for Q4, indicating significant losses; however, revenue surged by 167.5% year-over-year to $10.7 million, showcasing strong momentum in revenue growth.
- Revenue Growth Analysis: The revenue increase was primarily driven by the launch of new products and rising market demand, which not only enhanced the company's market share but also laid the groundwork for future profitability.
- Market Reaction: Despite the substantial revenue growth, the negative EPS may pressure investor confidence, leading to stock price volatility and reflecting market concerns regarding the company's financial health.
- Future Outlook: RYTHM must implement effective measures in upcoming quarters to improve profitability in order to maintain competitiveness in a growing market, especially in light of potential investor skepticism.
See More
Ryman Healthcare (NZSE: RYM) Shares Rise 19% in Quarter, Long-Term Holders Down 81%
- Quarterly Share Price Recovery: Ryman Healthcare's share price increased by 19% in the last quarter; however, long-term holders have faced an 81% decline over the past five years, highlighting a contradiction between short-term gains and long-term value erosion.
- Revenue Growth Analysis: Despite a 13% annual revenue growth rate over the last five years, the company has not been profitable, resulting in a 13% annual stock price decline, reflecting market concerns about its future profitability.
- Shareholder Return Discrepancy: Ryman Healthcare's total shareholder return (TSR) dropped by 77% over the past five years; although the stock price has performed poorly, the impact of reinvested dividends mitigates the decline, indicating the supportive role of dividends.
- Market Performance Comparison: Over the past year, Ryman Healthcare shareholders lost 31%, while the broader market gained 5.6%, indicating the company's performance significantly lags behind the market average, which may affect investor confidence.
See More
What Caused RYTHM (RYM) Stock to Surge More Than 23% Overnight?
Stock Performance: RYTHM Inc. shares rose 23.3% in after-hours trading to $30, despite a 21.52% drop during regular trading, closing at $24.33. The stock has seen a 46.54% decline over the past month.
Q3 Financial Results: The company reported a 98% increase in third-quarter revenue from continuing operations, reaching $4 million, while ending the quarter with $35.6 million in cash despite an $8.9 million operating loss.
Retail Expansion: RYTHM's THC beverage, Señorita THC Margaritas, launched in over 1,000 Circle K stores and select Target locations, marking significant retail expansion for hemp-derived THC products.
Strategic Developments: The company acquired intellectual property for several iconic brands and rebranded from Agrify Corporation to RYTHM Inc., positioning itself to benefit from the growing acceptance of THC beverages among consumers.
See More
RYTHM Reports Q4 Financial Results
- Financial Highlights: RYTHM reported a GAAP EPS of -$6.63 for Q4, indicating significant losses; however, revenue surged by 167.5% year-over-year to $10.7 million, showcasing strong momentum in revenue growth.
- Revenue Growth Analysis: The revenue increase was primarily driven by the launch of new products and rising market demand, which not only enhanced the company's market share but also laid the groundwork for future profitability.
- Market Reaction: Despite the substantial revenue growth, the negative EPS may pressure investor confidence, leading to stock price volatility and reflecting market concerns regarding the company's financial health.
- Future Outlook: RYTHM must implement effective measures in upcoming quarters to improve profitability in order to maintain competitiveness in a growing market, especially in light of potential investor skepticism.
See More
Ryman Healthcare (NZSE: RYM) Shares Rise 19% in Quarter, Long-Term Holders Down 81%
- Quarterly Share Price Recovery: Ryman Healthcare's share price increased by 19% in the last quarter; however, long-term holders have faced an 81% decline over the past five years, highlighting a contradiction between short-term gains and long-term value erosion.
- Revenue Growth Analysis: Despite a 13% annual revenue growth rate over the last five years, the company has not been profitable, resulting in a 13% annual stock price decline, reflecting market concerns about its future profitability.
- Shareholder Return Discrepancy: Ryman Healthcare's total shareholder return (TSR) dropped by 77% over the past five years; although the stock price has performed poorly, the impact of reinvested dividends mitigates the decline, indicating the supportive role of dividends.
- Market Performance Comparison: Over the past year, Ryman Healthcare shareholders lost 31%, while the broader market gained 5.6%, indicating the company's performance significantly lags behind the market average, which may affect investor confidence.
See More
What Caused RYTHM (RYM) Stock to Surge More Than 23% Overnight?
Stock Performance: RYTHM Inc. shares rose 23.3% in after-hours trading to $30, despite a 21.52% drop during regular trading, closing at $24.33. The stock has seen a 46.54% decline over the past month.
Q3 Financial Results: The company reported a 98% increase in third-quarter revenue from continuing operations, reaching $4 million, while ending the quarter with $35.6 million in cash despite an $8.9 million operating loss.
Retail Expansion: RYTHM's THC beverage, Señorita THC Margaritas, launched in over 1,000 Circle K stores and select Target locations, marking significant retail expansion for hemp-derived THC products.
Strategic Developments: The company acquired intellectual property for several iconic brands and rebranded from Agrify Corporation to RYTHM Inc., positioning itself to benefit from the growing acceptance of THC beverages among consumers.
See More
